Management


Craig Collard
President and Chief Executive Officer

Mr. Collard joined Veloxis in December of 2015 as the Chief Executive Officer.  He has over 23 years of experience in the pharmaceutical industry. 
 

Mr. Collard is currently a Board member of BioMarck Pharmaceuticals and Hilltop Home Foundation.  In 2003, Mr. Collard found Cornerstone Therapeutics where he became Chairman and CEO and was later sold to Chiesi Farmaceutici (2014). 
 

Mr. Collard started his career at Dura Pharmaceuticals where he served in numerous sales and marketing roles within the Company.  He left Dura in 1998 and joined DJ Pharma, Inc, which was sold to Biovail in 2000. 
 

Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia. 

Alastair McEwan
Executive Vice President, Chief Operating Officer

Alastair McEwan

McEwan has had broad experience from financial, M & A and general management roles and board appointments in private and public companies.  Before Veloxis he had a number of roles within Cornerstone Therapeutics (NASDAQ - CRTX) between 2005 and 2014.  He is a past chairman of the board of Cornerstone and was its executive CFO during the acquisition and integration of EKR and the subsequent sale of the expanded Cornerstone to Chiesi in 2014.

During the years between 2006 and 2009 he advised private equity firms in most of the larger CRO transactions following from his experience derived from Inveresk Research (NASDAQ - IRGI) and Averion International (NASDAQ – AVRO). 

At Inveresk he was a member of its Group Executive Board and President of its Global Clinical division.  He was directly responsible for the acquisition and turn- around of the ClinTrials group (NASDAQ – CCRO) and instrumental in the subsequent sale of the enlarged Inveresk Group to Charles River Laboratories in 2004 (NYSE – CRL).  At Averion he was a board member, interim CEO and chairman of its executive committee

He is a Bachelor of Commerce from the University of Edinburgh and a Chartered Accountant.

Johnny Stilou
Executive Vice President, Chief Financial Officer

Johnny Stilou

Mr. Stilou joined Veloxis in April 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations.

Prior to joining Veloxis, Mr. Stilou held a number of CFO positions with international technology and Medicare companies.

Mr. Stilou began his career with KPMG in Denmark in 1986. From 1995 until 2003 he held various senior finance positions within the GN Great Nordic group.

Mr. Stilou holds an MS degree in Economics and Business Administration from the Copenhagen Business School.

Mr. Breian Knudsen
Vice President, Technical Operations

Mr. Knudsen joined Veloxis in November 2007. He is responsible for technology transfer, process validation, and clinical and commercial manufacturing.

Mr. Knudsen has extensive experience within process and product development, technology transfer, process validation, and manufacture within the pharmaceutical industry.

Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S, where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes.

Mr. Knudsen holds an MSc degree in Pharmacy from the Pharmaceutical University of Copenhagen.

Ron Guido
Senior Vice President, Global Regulatory Affairs, Chief Compliance Officer

Ron Guido

Ron Guido has been employed in pharmaceutical development since 1980, in the areas of preclinical screening, clinical research, regulatory affairs, product development, and quality systems. Experience includes development strategy, merger and acquisition, as well as commercial support for new and marketed products. Past positions include Vice-President Regulatory, Retrophin, Inc; Senior Director and Therapeutic Area Head for Cardiovascular Medicine – Worldwide Regulatory Strategy for Pfizer, as well as senior roles with V.I. Technologies/ Precision Pharma Services, Whitehall-Robins Healthcare, Fresenius Pharma USA, and Wyeth-Ayerst Laboratories.  

His undergraduate education was in biology and psychology, and he holds an MS degree in Technical Communications from the Polytechnic University, New York, and an MSc degree in Pharmaceutical Medicine from Hibernia College, Dublin. He is currently Lecturer in Biology in the master's program in Biology of Biotechnology Program at Columbia University of the City of New York.